Find a Trial

1. ASPIRE IPF Study
   A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People with Idiopathic Pulmonary Fibrosis.
   Trial Location: NSW SA VIC Trial Category: Featured Trial Phase: Phase 2 Trial Status: Active, not recruiting Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 40 years Trial Participant Type: Patient
2. BI 1819479 Study
   This study is to find out whether a medicine called BI 1819479 helps people with Idiopathic Pulmonary Fibrosis (IPF).
   Trial Location: ACT New Zealand NSW TAS VIC Trial Category: Featured Trial Phase: Phase 2 Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 40 years Trial Participant Type: Patient
3. Avalyn AP01 MIST
   A Study Evaluating the Safety and Efficacy of AP01 in Participants with Progressive Pulmonary Fibrosis (PPF).
   Trial Location: ACT New Zealand NSW VIC WA Trial Phase: Phase 2 Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Progressive Pulmonary Fibrosis Trial Age Group: Over 18 years Trial Participant Type: Patient
4. The TELO-SCOPE Study
   Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis.
   Trial Location: NSW QLD VIC WA Trial Phase: Phase 2 Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Interstitial Lung Disease (ILD) Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Pulmonary Fibrosis (PF) Trial Age Group: Over 18 years Under 18 years Trial Participant Type: Patient
5. REBUILD-SM Trial
   A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (REBUILD-SM trial).
   Trial Location: NSW QLD VIC Trial Phase: Not applicable Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
6. CORAL
   Cough Reduction in IPF with nalbuphine ER.
   Trial Location: NSW SA VIC WA Trial Phase: Phase 2 Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 18 years Trial Participant Type: Patient
7. SNDX-6352-0506
   A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).
   Trial Location: QLD Trial Phase: Phase 2 Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Participant Type: Patient
8. BEACON-IPF
   A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF).
   Trial Location: New Zealand NSW QLD SA VIC WA Trial Phase: Phase 2 Trial Status: Recruiting Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 40 years Trial Participant Type: Patient
9. GRIPF
   Genetic Research in Idiopathic Pulmonary Fibrosis.
   Trial Location: NSW QLD SA VIC Trial Phase: Not applicable Trial Status: Recruiting Trial Type: Observational Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Pulmonary Fibrosis (PF) Trial Age Group: Over 18 years Under 18 years Trial Participant Type: Patient and Carer
10. SHIELD
    The SHIELD Whole Lung Lavage Observational Cohort Study.
    Trial Location: NSW QLD VIC Trial Phase: Not applicable Trial Status: Recruiting Trial Type: Observational Trial Disease Type: Silicosis Trial Age Group: Over 18 years Trial Participant Type: Patient
11. SINFONIA
    A clinical trial examining the benefits of SingINg For breathing in COPD aNd ILD pAtients.
    Trial Location: NSW VIC Trial Phase: Phase 3 Trial Status: Closed to recruitment Trial Type: Observational Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient and Carer
12. Novartis LTP001
    A participant and investigator-blinded, randomized, placebo-controlled, multicentre, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis.
    Trial Location: NSW QLD VIC WA Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 40 years Trial Participant Type: Patient
13. BI 1305-0013
    A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.
    Trial Location: NSW Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
14. COLDICE
    Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial disease allianCE
    Trial Phase: Not applicable Trial Status: Completed Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
15. HHF-ILD
    Handheld fan for breathlessness in Interstitial Lung Disease
    Trial Location: NSW Trial Phase: Not applicable Trial Status: Completed Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
16. STARSCAPE WA42293
    A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis.
    Trial Location: NSW Trial Phase: Phase 3 Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 18 years Trial Participant Type: Patient
17. GALACTIC-1
    A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks.
    Trial Location: NSW Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
18. SCENIC Trial
    Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF).
    Trial Location: NSW Trial Phase: Not applicable Trial Status: Discontinued Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
19. Endeavour Biomedicines ENV-101
    A phase 2, multi-center study evaluating the safety and efficacy of ENV-101 (taladegib) in subjects with idiopathic pulmonary fibrosis (IPF).
    Trial Location: NSW Trial Phase: Phase 2 Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 18 years Trial Participant Type: Patient
20. SPIRIT
    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Trial Location: VIC Trial Phase: Not applicable Trial Status: Discontinued Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 18 years Trial Participant Type: Patient
21. Blade Therapeutics
    A Phase 1a/1b, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Subjects with Lung Fibrosis or Liver Fibrosis
    Trial Location: NSW Trial Status: Discontinued Trial Type: Interventional Trial Disease Type: Pulmonary Fibrosis (PF) Trial Age Group: Over 18 years Trial Participant Type: Patient
22. Boehringer Ingelheim BI 1305-0014
    Trial Location: NSW Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
23. Lassen Therapeutics 1 LASN01
    A Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine the safety, tolerability, immunogenicity and pharmacokinetic properties of LASN01 in healthy subjects and in patients with idiopathic pulmonary fibrosis or thyroid eye disease.
    Trial Location: QLD VIC Trial Phase: Phase 1 Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Age Group: Over 18 years Trial Participant Type: Patient
24. BI 1305-0023
    A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1305-0023 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Trial Location: NSW Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
25. HIIT
    High intensity interval training in fibrotic interstitial lung disease
    Trial Location: NSW VIC Trial Phase: Not applicable Trial Status: Closed to recruitment Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
26. PFOX Trial
    Trial Location: NSW Trial Status: Completed Trial Type: Interventional Trial Disease Type: Interstitial Lung Disease (ILD) Trial Age Group: Over 18 years Trial Participant Type: Patient
27. Isabela 1&2
    A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis,
    Trial Status: Discontinued

Clinical trials listed on this website are limited to PACT endorsed studies. For a comprehensive list of all pulmonary fibrosis clinical trials please go to Australian Clinical Trials (australianclinicaltrials.gov.au).